Merck & Co Inc Dossier
Qualitative Analysis
Business overview
Merck & Co., Inc. (operating as MSD outside the United States and Canada) is a premier global research-intensive biopharmaceutical company. The company is dedicated to discovering, developing, and delivering innovative health solutions through its prescription medicines, biologic therapies, vaccines, and animal health products. Merck operates principally through two reportable segments: Pharmaceutical and Animal Health. The Pharmaceutical segment focuses on human health pharmaceutical products, consisting of therapeutic and preventive agents generally sold by prescription, alongside preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary medicines, vaccines, and health management solutions. Merck's global commercial footprint is supported by a robust research and development engine, with key therapeutic areas including oncology, vaccines, cardiometabolic diseases, immunology, and infectious diseases.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In February 2026, Merck restructured its Human Health division, splitting it into two distinct business units: a standalone Oncology unit and a Specialty, Pharmaceuticals & Infectious Diseases unit. This organizational change is designed to sustain long-term leadership in oncology while sharpening focus on a growing number of launches in other therapeutic areas.
Expected impact: Provides dedicated executive oversight and separate P&L management to better navigate the upcoming Keytruda platform transition and support an increasingly diversified pipeline.
Announced in mid-2025, this sweeping initiative involves an approximate 8% global workforce reduction (about 6,000 jobs) primarily targeting administrative, sales, and R&D positions, alongside real estate and manufacturing footprint optimization.
Expected impact: Aims to deliver approximately $3 billion in annual savings by 2027, which Merck plans to reinvest into newly launched drugs, R&D, and advanced data science capabilities.
Merck is actively working to extend the lifecycle of its blockbuster drug Keytruda ahead of its 2028 patent cliff. A key element of this strategy is the development and commercialization of a subcutaneous injection formulation, marketed as Keytruda Qlex, alongside new combination regimens.
Expected impact: Aims to transition patients to a more convenient administration method, preserving franchise value and staving off rapid biosimilar erosion post-2028.
Merck is expanding its domestic manufacturing capabilities, including the construction of a new 470,000 square-foot facility in Wilmington, Delaware, dedicated to producing Keytruda and other biologics, including antibody-drug conjugates (ADCs).
Expected impact: Secures domestic supply chains for critical biologics and supports the commercial launch of next-generation oncology therapies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquiring Terns Pharmaceuticals provides Merck with its mid-stage leukemia drug candidate (TERN-701), further diversifying and strengthening Merck's position in oncology as it prepares for the Keytruda patent cliff.
Financial impact: The transaction was valued at approximately $53 per share, representing a $6.7 billion equity value. It was not included in Merck's Q1 2026 financial guidance.
The acquisition strengthens and complements Merck's expanding respiratory portfolio, particularly through the addition of Cidara's Phase 3-ready antiviral candidate (CD388) for influenza.
Financial impact: Accounted for as an asset acquisition, resulting in a one-time, non-tax-deductible R&D charge of approximately $9.0 billion (or $3.65 per share) in Q1 2026. It is also expected to negatively impact GAAP and non-GAAP EPS by approximately $0.30 per share in the first 12 months due to financing and development costs.
Gives Merck ownership of Ohtuvayre, an FDA-approved treatment for chronic obstructive pulmonary disease (COPD), immediately enriching Merck's commercial respiratory portfolio.
Financial impact: The $10.0 billion transaction immediately added a commercial-stage asset to Merck's portfolio, with financing costs reflected in Merck's 2026 other expense guidance.
Strategic Partnerships
A landmark multi-year partnership to deploy an agentic AI platform powered by Google Cloud's Gemini Enterprise across Merck's R&D, manufacturing, commercial, and corporate functions.
Terms: Valued at up to $1.0 billion
A research and development agreement to apply AI, advanced analytics, and Mayo Clinic's multimodal clinical and genomic datasets to support drug discovery and precision medicine. The collaboration initially focuses on gastroenterology (IBD), dermatology (atopic dermatitis), and neurology (multiple sclerosis).
Terms: Terms not disclosed
A multi-year global collaboration utilizing Guardant's liquid and tissue biopsy portfolio (including the Guardant Infinity Smart platform) to support clinical trial enrollment and develop companion diagnostics for Merck's oncology pipeline.
Terms: Terms not disclosed